Hebei Changshan Biochem Pharma Asset Resilience Ratio
Hebei Changshan Biochem Pharma asset resilience ratio. Hebei Changshan Biochem Pharma (300255) has an Asset Resilience Ratio of -0.03% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hebei Changshan Biochem Pharma defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hebei Changshan Biochem Pharma (None–None)
Asset resilience ratio of Hebei Changshan Biochem Pharma from None to None. This chart shows how Hebei Changshan Biochem Pharma's Asset Resilience Ratio has changed over time. Read total liabilities of Hebei Changshan Biochem Pharma for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hebei Changshan Biochem Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hebei Changshan Biochem Pharma assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-1.20 Million | -0.03% |
| Total Liquid Assets | CN¥-1.20 Million | -0.03% |
Asset Resilience Insights
- Limited Liquidity: Hebei Changshan Biochem Pharma maintains only -0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Hebei Changshan Biochem Pharma Industry Peers by Asset Resilience Ratio
Compare Hebei Changshan Biochem Pharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Hebei Changshan Biochem Pharma Asset Resilience Ratio by Year (None–None)
Hebei Changshan Biochem Pharma asset resilience ratio by year from None to None. The table below shows the annual Asset Resilience Ratio data for Hebei Changshan Biochem Pharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Hebei Changshan Biochem Pharma
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China and internationally. The company offers crude heparin sodium, heparin sodium API, heparin sodium injections, low molecular weight heparin calcium i… Read more